BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coppolino G, Simeoni M, Summaria C, Postorino MC, Rivoli L, Strazzulla A, Torti C, Fuiano G. The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists. J Nephrol 2015;28:393-402. [DOI: 10.1007/s40620-015-0214-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Vasudevan A, Ardalan ZS, Ahmed N, Apostolov R, Gow PJ, Testro AG, Gane EJ, Angus PW. Long-term safety and efficacy of tenofovir disoproxil fumarate substitution for hepatitis B immunoglobulin following liver transplantation. JGH Open 2018;2:288-94. [PMID: 30619939 DOI: 10.1002/jgh3.12086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Chang KC, Yen YH, Lin MT, Hu TH. Does Nucleos(t)ide Analogues Treatment Affect Renal Function in Chronic Hepatitis B Patients Who Have Already Decreased eGFR? A Longitudinal Study. PLoS One. 2016;11:e0149761. [PMID: 26964034 DOI: 10.1371/journal.pone.0149761] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
3 Imam MH. The accelerated hepatitis B virus vaccination schedule among hemodialysis patients, does it work? A randomized controlled trial. J Nephrol 2017;30:803-9. [DOI: 10.1007/s40620-017-0443-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 Siakavellas S, Goulis J, Manolakopoulos S, Triantos C, Gatselis N, Tsentemidou E, Kranidioti H, Ζisimopoulos Κ, Τsoulas C, Dalekos G, Papatheodoridis G. Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. Ann Gastroenterol 2021;34:73-9. [PMID: 33414625 DOI: 10.20524/aog.2020.0525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Othumpangat S, Ray SD, Noti JD. Antiviral Drugs. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Elsevier; 2016. pp. 261-81. [DOI: 10.1016/bs.seda.2016.08.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Xu X, Thai H, Kitrinos KM, Xia G, Gaggar A, Paulson M, Ganova-Raeva L, Khudyakov Y, Lara J. Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction. BMC Bioinformatics 2016;17 Suppl 8:280. [PMID: 27587008 DOI: 10.1186/s12859-016-1116-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
7 Ghasemi F, Salehi M, Khoshnam Rad N, Khalili H. Tenofovir-Associated Acute Kidney Disease: Is it Different in HIV- and HBV-Infected Patients? Am J Ther 2019;26:e639-41. [PMID: 30252679 DOI: 10.1097/MJT.0000000000000847] [Reference Citation Analysis]
8 Simeoni M, Columbano V, Suzumoto Y, Salviano L, Capolongo G, Zacchia M, Del Vecchio Blanco F, Perna AF, Nigro V, Capasso G, Trepiccione F. Looking beyond Entecavir to discover Gitelman Syndrome in a 50 year-old man. QJM 2020;113:739-40. [PMID: 32221616 DOI: 10.1093/qjmed/hcaa104] [Reference Citation Analysis]
9 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021] [Cited by in Crossref: 1805] [Cited by in F6Publishing: 1711] [Article Influence: 361.0] [Reference Citation Analysis]
10 Simeoni M, Damiano S, Capolongo G, Trepiccione F, Zacchia M, Fuiano G, Capasso G. Rare Renal Diseases Can Be Used as Tools to Investigate Common Kidney Disorders. Kidney Dis (Basel) 2017;3:43-9. [PMID: 28868291 DOI: 10.1159/000475841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
12 Min IS, Lee CH, Shin IS, Lee NE, Son HS, Kim SB, Seo SY, Kim SH, Kim SW, Lee SO, Lee ST, Kim IH. Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate. Gut Liver 2019;13:93-103. [PMID: 30400723 DOI: 10.5009/gnl18183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
13 Strazzulla A, Coppolino G, Barreca GS, Gentile I, Rivoli L, Postorino MC, Mazzitelli M, Greco G, Costa C, Pisani V, Marascio N, Simeoni M, Focà A, Fuiano G, Foti D, Gulletta E, Torti C. Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals. Clin Mol Hepatol 2018;24:151-62. [PMID: 29684978 DOI: 10.3350/cmh.2017.0059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]